 |
|
|
|
|
|
NEWS RELEASE:
FOR IMMEDIATE RELEASE:
|
Beth Frost-Johnson, Sr. VP of Marketing
Merge Healthcare
(414) 977-4254
bethfj@merge.com
|
|
Rich Linden, President & CEO
Merge Healthcare
(414) 977-4000
rlinden@merge.com
|
|
Merge eMed Announces New Release of FUSION Matrix PACS™
Version 2.1 Offers New Diagnostic Reading Tools and Enhances Radiologist Productivity
Milwaukee, WI, January 31, 2006 – Merge eMed, a Merge Healthcare company and a leader in healthcare software and services, today announced that it has released FUSION Matrix PACS, version 2.1. This newest release introduces several key enhancements to help radiologists efficiently read studies, including the ability to query and retrieve studies from third-party DICOM sources, reserve studies, and mark studies as preliminary. In addition, FUSION Matrix PACS 2.1 has added new tools such as triangulation, which lets the user easily define a target point on an image to view the corresponding anatomical position in other series. FUSION Matrix PACS is sold as a stand-alone PACS solution or as part of FUSION RIS/PACS MX, which integrates business and clinical workflow.
“This newest release follows a product innovation process that includes conceptual design based on customer input, customer research and usability testing,” says Barbara Dumery, Senior Product Manager. “FUSION Matrix PACS continues to be focused on creating the absolute best workflow environment for our customers along with a highly productive workspace for radiologists.”
“We are very pleased with this newest version of the FUSION Matrix PACS,” says Dr. Ramin Abrahim of Washington Radiology Associates. “We have already seen efficiencies in study assignment and retrieval, and the radiologists are happy to have even more flexibility in their reading worklist. Graphic marking of high priority studies on the worklist ensures prompt reading of those studies. The triangulation feature is invaluable in analysis of complex structures and pathology in MRI studies with numerous sequences in multiple planes.” Washington Radiology Associates is a comprehensive outpatient imaging practice with six clinical offices located throughout the metropolitan DC area and a medical staff of 24 board certified and fellowship trained sub-specialty physicians.
# # #
Merge Healthcare is a market leader in the development and delivery of medical imaging and information management software and services. Our innovative software solutions use leading-edge imaging software technologies that accelerate market delivery for our OEM customers, while our end-user solutions improve our customers' productivity and enhance the quality of patient care they provide. For additional information, visit our website at www.mergehealtcare.com.
Merge eMed, a Merge Healthcare company,is focused on accelerating productivity for radiology departments and specialty practices, imaging centers and hospitals. By combining sophisticated RIS, PACS, advanced visualization and clinical imaging applications, Merge eMed delivers integrated end-to-end software solutions and professional services that are transforming the way our customers interact with referring physicians, manage their workflow, position their businesses in their markets and deliver imaging and information services to their customers. For additional information, visit our website at www.merge-emed.com.
|
Attn: Beth Frost-Johnson
Merge Healthcare
6737 West Washington St.
Suite 2250
Milwaukee, WI 53214
|
|
|
|
|
|
| Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, the forward-looking statements based on a number of factors, including, but not limited to, the uncertainty created by, the adverse impact on relationships with customers, potential customers, suppliers and investors potentially resulting from, and other risks associated with, the changes in the Company’s senior management; costs, risks and effects of the investigation by the Audit Committee of the Board of Directors; the impact of the restatement of financial statements of the Company and other actions that may be taken or required as a result of such restatement; the Company's inability to timely file reports with the Securities and Exchange Commission; risks associated with the Company's inability to meet the requirements of The NASDAQ Stock Market for continued listing, including possible delisting; costs, risks and effects of legal proceedings and investigations, including the informal, non-public inquiry being conducted by the Securities and Exchange Commission and class action, derivative, and other lawsuits; risks in product and technology development, market acceptance of new products and continuing product demand, the impact of competitive products and pricing, ability to integrate acquisitions, changing economic conditions, credit and payment risks associated with end-user sales, dependence on major customers, dependence on key personnel, and other risk factors detailed in the Company’s filings with the Securities and Exchange Commission. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements contained herein to reflect future events, developments, or changed circumstances, or for any other reason.
|
|
|
